【4503】アステラス製薬 : Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of OS and rPFS

Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of OS and rPFS

出所:株経通信(株式会社みんかぶ)
PDFをダウンロード